SCHEMBL3877480

SCHEMBL3877480

Cc1ccc(-c2nc(N3CCOCC3)nc(N3CCN(c4ccccn4)CC3)n2)c2ccccc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 6/20 0.51
MTOR P42345 6/20 0.51
HPGD P15428 5/20 0.50
ALDH1A1 P00352 5/20 0.50
HSD17B10 Q99714 3/20 0.50
PIK3R1 P27986 4/20 0.47
NPC1 O15118 1/20 0.47
HK1 P19367 1/20 0.47
RAB9A P51151 1/20 0.47
HKDC1 Q2TB90 1/20 0.47
KDM4E B2RXH2 4/20 0.47
SMN1; SMN2 Q16637 2/20 0.46
TSHR P16473 2/20 0.46
MAPT P10636 2/20 0.46
LMNA P02545 1/20 0.46
TP53 P04637 1/20 0.46
GAA P10253 1/20 0.45
ALOX15 P16050 2/20 0.44
MAPK1 P28482 2/20 0.44
USP2 O75604 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3878604 0.87 ALDH1A1 (0.52) PIK3CAMTORHPGDALDH1A1HSD17B10
SCHEMBL3879522 0.86 HSD17B10 (0.52) PIK3CAMTORHPGDALDH1A1HSD17B10
SCHEMBL3887124 0.85 HPGD (0.50) PIK3CAMTORHPGDALDH1A1HSD17B10
SCHEMBL3884243 0.85 PIK3CA (0.54) PIK3CAMTORHPGDALDH1A1HSD17B10
SCHEMBL3879980 0.84 CNR2 (0.51) PIK3CAMTORHPGDALDH1A1HSD17B10
SCHEMBL3884202 0.84 PIK3CA (0.50) PIK3CAMTORHPGDALDH1A1HSD17B10
SCHEMBL3878071 0.84 LRRK2 (0.51) PIK3CAMTORHPGDALDH1A1HSD17B10
SCHEMBL3876033 0.80 HPGD (0.50) PIK3CAMTORHPGDALDH1A1HSD17B10
SCHEMBL3880853 0.80 ALDH1A1 (0.50) PIK3CAMTORHPGDALDH1A1HSD17B10
SCHEMBL13761287 0.79 HTT (0.61) PIK3CAMTORHPGDALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7566712-B2 Biaryl piperazinyl-pyridine analogues NEUROGEN CORPORATION (US) 2009-07-28 US claimed
US-7566712-B2 Biaryl piperazinyl-pyridine analogues NEUROGEN CORPORATION (US) 2009-07-28 US disclosed
US-7566712-B2 Biaryl piperazinyl-pyridine analogues NEUROGEN CORPORATION (US) 2009-07-28 US disclosed
US-7566712-B2 Biaryl piperazinyl-pyridine analogues NEUROGEN CORPORATION (US) 2009-07-28 US disclosed
US-20070027155-A1 Biaryl piperazinyl-pyridine analogues NEUROGEN CORPORATION 2007-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027155-A1 Biaryl piperazinyl-pyridine analogues GPR174, GPR68, PPARG PIK3CA 1107/4885MTOR 2949/4885HPGD 952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.